Yali Fu

4.4k total citations · 1 hit paper
15 papers, 1.0k citations indexed

About

Yali Fu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yali Fu has authored 15 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Yali Fu's work include Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Research Studies (3 papers). Yali Fu is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Research Studies (3 papers). Yali Fu collaborates with scholars based in China, United States and United Kingdom. Yali Fu's co-authors include Anita H. Clayton, Leonard R. Derogatis, Diane J. Lewis-D’Agostino, Glen Wunderlich, Egbert F. Smit, Harry J.M. Groen, William Pao, D. Ross Camidge, Scott Gettinger and Leora Horn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Yali Fu

15 papers receiving 991 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Validation of the Female Sexual Distress Scale-Revised for Assessing Distress in Women with Hypoactive Sexual Desire Disorder

2007 560 citations Leonard R. Derogatis, Anita H. Clayton et al. The Journal of Sexual Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yali Fu China	9	435	361	339	206	181	15	1.0k
Dawn Odom United States	14	250 0.6×	140 0.4×	111 0.3×	56 0.3×	100 0.6×	46	681
Tom Ehlen Canada	11	113 0.3×	448 1.2×	186 0.5×	176 0.9×	67 0.4×	15	2.3k
M. Heywood Canada	18	110 0.3×	440 1.2×	141 0.4×	111 0.5×	67 0.4×	26	1.5k
Laurie Tuason United States	16	51 0.1×	467 1.3×	333 1.0×	149 0.7×	42 0.2×	27	1.1k
Mark Reynolds United States	12	34 0.1×	213 0.6×	310 0.9×	185 0.9×	36 0.2×	23	924
E. Ehrnrooth United States	17	213 0.5×	861 2.4×	510 1.5×	368 1.8×	22 0.1×	57	1.7k
Jimmy Hwang United States	16	36 0.1×	272 0.8×	111 0.3×	95 0.5×	56 0.3×	38	882
Howard I. Scher United States	10	44 0.1×	481 1.3×	341 1.0×	182 0.9×	16 0.1×	17	961
Lynne P. Taylor United States	18	60 0.1×	137 0.4×	149 0.4×	111 0.5×	69 0.4×	48	760

Countries citing papers authored by Yali Fu

Since Specialization

Citations

This map shows the geographic impact of Yali Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yali Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yali Fu more than expected).

Fields of papers citing papers by Yali Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yali Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yali Fu. The network helps show where Yali Fu may publish in the future.

Co-authorship network of co-authors of Yali Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Yali Fu. A scholar is included among the top collaborators of Yali Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yali Fu. Yali Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Piha‐Paul, Sarina A., Macarena I. de la Fuente, Fábio M. Iwamoto, et al.. (2024). Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3107–3107. 3 indexed citations

Johnson, Melissa L., Juanita Lopez, Patricia LoRusso, et al.. (2021). 493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A525–A525. 6 indexed citations

Fu, Yali, et al.. (2019). Neutrophil to Lymphocyte Ratio in Retroperitoneal Liposarcoma and Other Prognostic Factors. SHILAP Revista de lepidopterología. 1 indexed citations

Li, Lin, Lihua Jia, Yali Fu, et al.. (2019). A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study. Journal of Infection and Public Health. 12(6). 789–793. 12 indexed citations

Tang, Chuanhao, Li Lin, Wei Zhou, et al.. (2019). CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck. Chinese Journal of Cancer Research. 31(6). 901–909. 3 indexed citations

Li, Li, Chuanhao Tang, Chao Meng, et al.. (2018). Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR‑TKI therapy in metastatic lung adenocarcinoma. Oncology Letters. 16(2). 2382–2390. 9 indexed citations

Fu, Yali, Xing Wei, Lin Li, Weiran Xu, & Jun Liang. (2018). Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors. Thoracic Cancer. 9(5). 542–547. 27 indexed citations

Janjigian, Yelena Y., Egbert F. Smit, Harry J.M. Groen, et al.. (2014). Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations. Cancer Discovery. 4(9). 1036–1045. 295 indexed citations

Cheng, Jingyi, et al.. (2014). Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clinical Radiology. 70(2). 128–137. 26 indexed citations

10.

Li, Shanshan, Yan Wang, Chuanhua Zhao, et al.. (2013). [Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].. PubMed. 35(4). 273–6. 1 indexed citations

11.

Liu, Xiaojing, Yan Wang, Chuanhua Zhao, et al.. (2013). [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].. PubMed. 35(9). 666–71. 8 indexed citations

12.

Grève, Jacques De, Teresa Morán, Marie-Pascale Graas, et al.. (2013). Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 31(15_suppl). 8063–8063. 9 indexed citations

13.

Janjigian, Y. Y., Egbert F. Smit, Leora Horn, et al.. (2012). Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors. Annals of Oncology. 23. ix401–ix401. 46 indexed citations

14.

Derogatis, Leonard R., Anita H. Clayton, Diane J. Lewis-D’Agostino, Glen Wunderlich, & Yali Fu. (2007). Validation of the Female Sexual Distress Scale-Revised for Assessing Distress in Women with Hypoactive Sexual Desire Disorder. The Journal of Sexual Medicine. 5(2). 357–364. 560 indexed citations breakdown →

15.

Sunada, Ichiro, et al.. (1996). Local multicystic encephalopathy: case report.. PubMed. 13(5). 255–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact